Related Experiment Video

Updated: Mar 23, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Erratum to: Reassessing the risk of natalizumab-associated PML

Joseph R Berger1,2, Robert J Fox3,4

  • 1Multiple Sclerosis Division of the Department of Neurology, University of Pennsylvania, 3400 Spruce St., 3 W Gates, Philadelphia, PA, 19104, USA. joseph.berger@uphs.upenn.edu.

Journal of Neurovirology
|March 31, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

8.4K
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.9K

Related Experiment Videos

Last Updated: Mar 23, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

8.4K
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.9K

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

314
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
314
Arboviral Encephalitis01:25

Arboviral Encephalitis

8
Arboviral encephalitis refers to brain inflammation caused by arthropod-borne viruses, particularly those transmitted through mosquito vectors. Among these, West Nile virus (WNV), a member of the Flaviviridae family, is a significant public health concern. WNV is an enveloped, positive-sense, single-stranded RNA virus. Human infection typically begins when an infected mosquito introduces the virus into the dermis during feeding. The primary transmission cycle involves birds as amplifying hosts...
8

Articles linked to this work by shared authors, journal, and citation graph.

Assessing the feasibility, theoretical interest, and observed behaviors of adding genetic data to a patient-reported multiple sclerosis registry.

Multiple sclerosis journal - experimental, translational and clinical·2026

Clinicians' and patients' perspectives of a mobility technician role in the hospital to promote ambulation: A qualitative study.

Journal of hospital medicine·2026

Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years.

Multiple sclerosis and related disorders·2026

Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases.

Multiple sclerosis journal - experimental, translational and clinical·2026

Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data.

Expert opinion on investigational drugs·2026

The EBV timing hypothesis: How the age of primary infection may explain global variation in multiple sclerosis.

Multiple sclerosis and related disorders·2026

CRISPR-mediated excision of HTLV-1 reduces proviral loads in PBMCs from HAM/TSP patients.

Journal of neurovirology·2026

From viral epigenetic reprogramming to neuroinflammation: Mechanisms driving neurodegeneration.

Journal of neurovirology·2026

Impact of cannabis use on white matter hyperintensities in adults with and without chronic HIV disease.

Journal of neurovirology·2026

Systematic review and multilevel meta-analysis of preclinical survival outcomes of Zika virus-based oncolytic therapy in glioblastoma.

Journal of neurovirology·2026

Possible involvement of viral infection in the pathogenesis of myasthenia gravis.

Journal of neurovirology·2026

SARS-CoV-2 disrupts the integrity of a human blood-brain barrier model in the absence of infection.

Journal of neurovirology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us